ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018
Improving Carboplatin Dosing Based on Estimated GFR.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Calvert Formula Modification for Optimized Carboplatin Dosing in Breast Cancer with Preserved Renal Function.Pharmaceutics · 2026Article
- Pharmacokinetic Study of Carboplatin Using Various Overweight-Correcting Dosing Algorithms and Biomarkers in Patients With Varying BMI Categories.Therapeutic drug monitoring · 2025Article
- Aligning kidney function assessment in patients with cancer to global practices in internal medicine.EClinicalMedicine · 2025Review
- Review
- Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.EClinicalMedicine · 2025Review
- Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice.BMC cancer · 2022Article
- Improving the tolerability of osimertinib by identifying its toxic limit.Therapeutic advances in medical oncology · 2022Article
- Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters.Cancers · 2021Article
- Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.Cancer research and treatment · 2021Article
- Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.Pediatric nephrology (Berlin, Germany) · 2021Article
- CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury.Kidney360 · 2021Article
- Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.Cancer chemotherapy and pharmacology · 2020Article
- Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS.Journal of pharmaceutical and biomedical analysis · 2020Article
- Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.Cancer chemotherapy and pharmacology · 2019Article
- Performance of Glomerular Filtration Rate Estimating Equations Before and After Bariatric Surgery.Kidney medicineArticle
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.